Exercise Stress Testing in Healthy Subjects During Cholinergic Stimulation after a Single Dose of Pyridostigmine

Salvador M. Serra, Ricardo Vivacqua C. Costa, Bianca Gouvêa Bastos, Kelb Bousquet Santos, Sérgio Henrique Rodolpho Ramalho, Antonio Claudio Lucas da Nóbrega

Niterói, RJ – Brazil

Objective - The evaluation, by exercise stress testing, of the cardiorespiratory effects of pyridostigmine (PYR), a reversible acetylcholinesterase inhibitor.

Methods - A double-blind, randomized, cross-over, placebo-controlled comparison of hemodynamic and ventilation variables of 10 healthy subjects who underwent three exercise stress tests (the first for adaptation and determination of tolerance to exercise, the other two after administration of placebo or 45mg of PYR).

Results - Heart rate at rest was: 68±3 vs 68±3bpm before and after placebo, respectively (P=0.38); 70±2 vs 59±2bpm, before and after pyridostigmine, respectively (P<0.01). During exercise, relative to placebo: a significantly lower heart rate after PYR at, respectively, 20% (P=0.02), 40% (P=0.03), 80% (P=0.05) and 100% (P=0.02) of peak effort was observed. No significant differences were observed in arterial blood pressure, oxygen consumption at submaximal and maximal effort, exercise duration, respiratory ratio, CO₂ production, ventilation threshold, minute ventilation, and oxygen pulse.

Conclusion - Pyridostigmine, at a dose of 45mg, decreases heart rate at rest and during exercise, with minimal side effects and without interfering with exercise tolerance and ventilation variables.

Keywords: autonomic nervous system, pyridostigmine, exercise stress testing.

The autonomic nervous system interferes with the course of cardiovascular disease. The imbalance between sympathetic and parasympathetic activity on the heart influences the prognosis of heart disease, increasing the risk of events.¹

Sympathetic activity reduction is associated with decreased cardiovascular morbidity and mortality.²,³ Yet, although experimentally increased parasympathetic activity protects the ischemic myocardium from major cardiovascular events by raising the ventricular fibrillation threshold,⁴⁻⁶, few studies aimed at autonomic equilibration via pharmacological parasympathetic stimulation are available.⁷⁻¹³

Recent work has shown that pyridostigmine (PYR), a reversible acetylcholinesterase inhibitor used in high oral doses for the treatment of myasthenia gravis, may become an alternative pharmacological treatment for obtaining autonomic system equilibration via efferent cholinergic stimulation of the heart.¹⁴⁻¹⁶

We conducted the initial clinical research on this drug to study the effects of a single dose of PYR on functional responses of the integrated cardiopulmonary system of healthy subjects during exercise, evaluating their responses to a programmed cardiovascular exercise protocol.

Methods

At first, a pilot study using a similar design as the present one, evaluated the effects of 30mg of PYR on healthy subjects undergoing cardiovascular exercise stress tests. At that dose, the drug reduced resting heart rate, but did not lead to other significant modifications or to adverse effects; these observations suggested that there was a safety margin for the present studies in which a higher dose (45mg) of PYR was used.¹⁷

Ten healthy volunteers were selected on the basis of the absence of history, signs, symptoms, or results of a physical examination suggestive of heart disease or any other acute or chronic disease. All subjects underwent a resting 12-lead electrocardiogram (ECG) and an initial
echocardiography to identify functional or structural clinically undetected heart disease. Athletes, drug users, those with cardiac conduction or mitral valve prolapse, asthma, diabetes mellitus, conditions preventing exercise, and individuals showing intolerance to PYR or similar drugs were excluded from the study. The Ethics in Research Committee of the University Hospital Antonio Pedro, School of Medicine, UFF and the Ethics in Research Committee of the Pró-Cardíaco Hospital approved the study protocol. All volunteers signed a statement of informed consent once they understood the objectives and general details of the study. No funding from either pharmaceutical or equipment industries were received in the study.

Volunteers underwent three cardiopulmonary exercise test sessions according to a randomized, cross-over, double blind, placebo-controlled protocol. Increases in exercise intensity during the tests were not staggered and occurred in continuous increments according to the individualized ramp protocol.

The first test was intended to familiarize with the volunteers with the equipment and to identify the maximal aerobic capacity to exercise, planned to be reached after the ideal time period of 10min. The two subsequent tests should, for the same time intervals, have equal exercise intensities for each individual subject. Each volunteer was given placebo or 45mg of pyridostigmine bromide orally, in random fashion. The commercially available Mestinon tablets (Roche Laboratories, Brazil, batch 738392) was the source of the drug.

The same medical investigator made all three cardiopulmonary exercise tests at the same time of the day. Participants had a similar light meal, followed by a 2-h period of fasting before the administration of drug or placebo.

Prior to the second and third stress tests, the following steps were applied in successive order: 1) a 15-min resting period in the supine position; 2) verification of arterial blood pressure at 5-min intervals in the right arm, for a total of three (averaged) values 3) 12-lead ECG, in the supine position; 4) record of heart rate of the ECG, after digital amplification, on lead D; 5) the administration of placebo or of a 45-mg PYR tablet; 6) 120min of clinical monitoring, in the absence of food intake; 7) successive repetition of items 1,2,3 and 4; 8) performance of the cardiopulmonary exercise stress test, applying the individualized ramp protocol.

During the cardiopulmonary exercise stress tests, expired gases were analyzed using the Teem 100 (AeroSport, USA); the treadmill, model 10200 (Inbramed, Brazil) with exercise intensity computer-directed increments, and the Elite 1.1 system of registration (Micromed, Brazil)

Every minute during exercise, the subjective feeling of tiredness was obtained from the volunteers, using Borg’s scale from 0 to 10. Upon reaching this value, subjects were stimulated to carry on until their maximal limit, considered exhaustion.

Four ECG leads were monitored during the tests, with registration of the 13 leads, immediately prior to beginning, at every minute of effort, at peak effort and until the third minute in the recovery phase. The arterial blood pressure during these moments was also measured, sing a mercury column device (Oxigel, Brazil); to reduce the possibility of errors during the measurements, fractions of 2mmHg were considered.

Peripheral oxygen saturation was continuously measured during stress and until the 3rd minute of recovery, by a 3700 digital Biox oximeter (Ohmeda, USA).

Pulmonary ventilation (PV), oxygen consumption (VO2), carbon dioxide production (VCO2), oxygen (PV/VO2), and carbon dioxide (PV/VCO2) ventilation equivalents, and oxygen pulse (V02/HR) were recorded following every 20s of effort, up to the 3rd minute of the recovery phase. The spirometer used in all volunteers was of medium flow and had been previously validated by an international university institution.

The beginning of the nonlinear ventilation was considered to identify ventilation thresholds. This point was identified by visual analysis of a minute volume vs. exercise time plot, evaluated by two experienced physicians, each of whom did not know each other’s choices. Although other variables have been used for the study of the ventilation threshold, our method has been traditionally employed and was considered adequate.

The variables studied during the exercise tests were individually compared at equivalent exercise levels corresponding to respectively, 20, 40, 60 80, and 100 percent of the maximal time of exercise performance. Data were tested to ascertain their normal distribution. They underwent two-way repeated measurements analysis of variance (ANOVA), in which main factors were the drug (placebo or pyridostigmine) and time (before and after treatment, at different exercise levels). Once significance was reached, post hoc analysis was made by Student’s t-test for paired measurements, applying Bonferroni’s correction. For proportion analysis the chi-square test was used, taking the number of collateral effects in the individuals into consideration. P<.05 was considered the level of statistical significance.

**Results**

Seven of the 10 volunteers were female. Average age of the group was 28±2 years; average weight, 67.4±52kg; height, 170±2cm. According to the randomization protocol, six volunteers used PYR prior to the first test, placebo prior to the second, and an inverse sequence in the other four.

There was a greater number of adverse effects following 45mg of PYR compared to placebo (P=0.041). No subject was excluded due to these adverse; on no occasion was drug treatment of these effects required. Following PYR, 4 volunteers had the following four symptoms, all of mild intensity: sialorrhea (three), abdominal pain and diarrhea (one of the three who had sialorrhea), and epigastric pain (one).

PYR did not interfere with the time of maximal exercise duration in the ramp protocol, which was as follows PYR:
10.4±0.5 min; placebo: 10.8±0.6 min; (P=0.36). Similarly, PYR did not interfere with the absolute values of ventilation threshold (PYR: 24.3±2.6 ml/kg/min; placebo: 25.7±2.7; (P=0.19). Relative to percent maximal oxygen consumption, the ventilation threshold following PYR was 65.9±1.6%, and after placebo, 66.0±1.9% (P=0.48).

Compared with the postplacebo effect, following PYR, heart rate at rest was reduced (pre-PYR: 70±2 bpm; post-PYR: 59±2 bpm; (P=0.004); placebo: 68±3 bpm; postplacebo: 68±3; (P=0.38) (Figure 1), without interference in the PR interval: pre-PYR: 140.6±7.0 ms; post-PYR: 140.7±6.9 ms; (P=0.86).

During effort, a significant reduction in heart rate relative to placebo occurred at 20% (p=0.02); at 40% (p=0.03); at 80% (p=0.05), and at 100% (p=0.02) (Figure 2).

PYR did not interfere with systolic blood pressure, (at rest - pre-PYR: 110±4 mmHg; post-PYR: 106±4 mmHg; (P=0.90), or diastolic blood pressure (at rest - pre-PYR: 65±2 mmHg; post–PYR: 65±2 mmHg; p=0.38).

Statistics of the metabolic data of cardiopulmonary exercise stress tests did not show an effect of 45 mg of pyridostigmine: respiratory maximal ratio – post-PYR: 1.09±0.02, postplacebo: 1.13±0.02 (P=0.40); oxygen pulse at maximal effort (in mlO₂.kg⁻¹.min⁻¹), bpm⁻¹ - post-PYR: 14.4±1.4; postplacebo: 14.4±1.6 (P=0.93). Ventilation/minute at maximal effort – post-PYR: 68.1±6.6 L.min⁻¹; postplacebo: 74.6±6.7 L.min⁻¹ (P=0.36); production of CO₂ at maximal effort - post-PYR: 2.85±0.31 L.min⁻¹; postplacebo: 3.25±0.31 L.min⁻¹ (p=0.22). No differences relative to oxygen consumption, in mL.kg⁻¹.min⁻¹, measured at 20% - post-PYR: 12.9±1.3, postplacebo: 12.5±1.9; at 40% - post-PYR: 19.0±2.8, postplacebo: 19.4±3.1; at 60% - post-PYR: 26.0±3.9, postplacebo: 26.3±4.0; at 80% - post-PYR: 32.8±4.2, postplacebo: 33.2±4.2 and at 100% of maximal effort-post-PYR: 37.4±4.0, postplacebo: 38.9±4.3 (P=0.74) were observed (Figure 3).

**Discussion**

The most relevant observation of our study was the demonstration that pyridostigmine, at an oral dose of 45 mg, reduced heart rate not only at rest, but also during stress, when there is a progressive increase in sympathetic autonomic activity. Others 14-16,19,20 using a dose of 30 mg of PYR had already observed the reduction in heart rate at rest shown in this study.

Few studies of the effects of PYR during exercise are available. Arad et al. 21, studied eight hypertensive individuals on beta-blocker treatment, who underwent exercise stress on the ergometer, without analysis of expired gases, following the ingestion of 30 mg of PYR. No reduction in heart rate was observed. Stephenson and Kolka 19, on the other hand, following the administration of 30 mg of PYR, observed an average reduction in heart rate of 9 beats per min in five individuals who had previously undergone a 30-min period of ergometer exercise, at an intensity of 55% of peak VO₂. Heart rate was measured at the 25th minute of exercise. Our observation of an average reduction in heart rate of 8 bpm at 40% of peak effort, using 45 mg of PYR parallels the results of Stephenson and Kolka 19. The divergence between our results on heart rate, and those of Arad et al. 21 may be attributed to the concomitant use of a cardiodepressor agent by these authors.

A 15% to 40% reduction in serum cholinesterase activity was obtained in previous studies using 30 mg of PYR 15,22. The presently observed reduction of heart rate following PYR administration indicates that the volunteers were indeed under acetylcholinesterase blockade.

Because of the bradycardiac effect of PYR at rest and during effort, evidenced in the present study, one can expect that PYR may have a beneficial effect on the decrease heart rate per se. According to Levine 23, all mammals have an in-
verse semilogarithmic relationship between heart rate and life expectancy. A study on a universal biological scale of mortality suggests that basal energy consumption per body atom per heart beat is the same in all animals: approximately $10^4$ molecules per beat, suggesting that life expectancy is predetermined by the energetic bases of the living cell, and that heart rate reflects an epiphenomenon in which heart rate itself is the marker of metabolic expenditure. Levine recommends that research should be done to confirm that human life can be really extended by reducing heart rate, and that clinical studies to evaluate the therapeutic effect of brady-cardia should be performed.

Several studies have shown that subjects with lower heart rates tend to have lower mortality rates consequent to stroke, cancer, coronary artery disease as well as a lower global mortality rate. Recent research involving 4,756 subjects of both sexes between 40 and 80 years of age also concluded that heart rate is a predictor of mortality, independently of other associated risk factors. Without discarding possible benefits inherent to a reduction of heart rate in young healthy individuals, it should be emphasized that our volunteers differ from some populations reported in these studies.

Our work did not demonstrate an effect of pyridostigmine on systolic and diastolic blood pressure levels at rest or during exercise. Although we did not expect an alteration because only healthy individuals took part in this research, the normal pressure response during exercise under enhanced cholinergic stimulation, indirectly suggests that ventricular function took place without limitations. The normal kinetics of the oxygen pulse in volunteers during effort supports this observation. On the other hand, different from Arad et al., in our study diastolic blood pressure during rest or stress showed no difference following PYR administration when compared to placebo. The concomitant use of a beta-blocker by patients in the study by Arad et al. may have induced a more effective opposition to the vasoconstrictor action of the beta-blocker, reducing vascular peripheral resistance during stress and determining a fall in diastolic blood pressure.

Regarding the cardiopulmonary stress test, a procedure known to be of high reproducibility in the evaluation of metabolic parameters during exercise, pyridostigmine did not cause significant changes in CO$_2$ production and expired minute volume. These data acquire greater significance because cholinesterase inhibitors like PYR effect the bronchial tree favoring smooth muscle contraction. This has induced in caution in its prescription to asthmatic patients and is the reason for their exclusion from our study.

Because PYR led to reduced heart rate without modifying oxygen consumption during stress, we expected to observe an increase in oxygen pulse compared to placebo. However, because oxygen pulse is also influenced by the arteriovenous difference in O$_2$ content, it is possible that a decreased cardiac output during exercise occurred, so that VO$_2$ was maintained at the expense of an increase in the arteriovenous oxygen difference. Another explanation could be the scatter of VO$_2$ and heart rate data.

PYR did not interfere in the duration in minutes of the test or in the submaximal and maximal VO$_2$, or the ventilation threshold. These data indicate the favorable metabolic effect of PYR and contrasts with the results of previous work evaluating healthy individuals using beta-blockers. Some of these studies showed reduced submaximal oxygen consumption and a decrease of 40 to 60 s in exercise duration. Thus, the reduced heart rate caused by PYR, by not involving conditions that may lead to fatigue during submaximal exercise may be interpreted as favorable by avoiding the need to limit subjects’ daily activities.

Autonomic nervous system dysfunction is associated with an unfavorable prognosis in various cardiovascular diseases. Autonomic in balance may precipitate sudden death and a worsening of chronic coronary artery disease, of acute myocardial infarction, hypertrophic cardiomyopathy, cardiac failure, dilated cardiomyopathy, syndrome X, hypertension, insulin resistance, and diabetes mellitus.

Pharmacological reduction in sympathetic activity with beta-blockers in ischemic heart disease decreases cardiovascular mortality by approximately 23%, 7-3, 30. This and other favorable results have led to the generalization of the prescription of this group of drugs and the later discovery of beta-blockers with other associated effects. However, the specific reduction of parasympathetic activity in acute myocardial infarct survivors is an indication for a poor prognosis. Several studies associate decreased vagal activity with an increase in cardiovascular mortality. Successful coronary thrombolysis performed up to 12 h after an acute myocardial infarct is associated with increased heart rate variability, indicating greater vagal activity. Functional autonomic preservation of the heart following restoration of coronary patency is one of the factors determining a better prognosis.

Thus, there is a confluence of opinions attributing a worse prognosis, not only to the increase in sympathetic activity but also to reduced parasympathetic activity, which appears to effectively contribute to such unfavorable prognoses.

Few studies, however, were designed to show the pharmacological effects of increased parasympathetic activity. In 1993, four independent groups published articles evaluating the effects of scopolamine and agents that at low doses act as cholinomimetics. They showed a reduction in heart rate and an increase in its variability. Hull et al. in 1995 failed to identify modifications of ventricular fibrillation threshold following the use of scopolamine. This result did not confirm studies showing a protective antifibrillatory effect following experimental parasympathetic stimulation. The paradoxical effect of scopolamine, which at high doses becomes a cholinergic blocker, limits the usefulness of studies using higher doses of this drug.

Recently, the ATRAMI study designed to investigate vagal reflexes in 1284 patients within less than 28 days follo-
wring an acute myocardial infarction showed the prognostic value of vagal activity, independently of ventricular function or the presence of cardiac arrhythmia. In their conclusion, the authors emphasized the need for research enabling the therapeutic correction of autonomic in balance, thus contributing to the reduction of cardiac mortality.

Being a reversible inhibitor of acetylcholinesterase and thus resulting in greater availability of acetylcholine at effector organs, pyridostigmine has been studied for its a dose-dependent effect, for being active following oral administration, for having been used for decades at high doses for the treatment of myasthenia gravis, and by being associated with a low incidence of collateral effects.

Recent studies evaluating the effects of pyridostigmine on the cardiovascular system of healthy subjects have shown: 1) absence of hemodynamic or functional ventricular damage on echocardiography; 2) increased heart rate variability for over 24h; 3) attenuation of the double process of cardiac remodeling and progression of left ventricular hypertrophy.

In conclusion, the cholinergic effect of pyridostigmine at the dose of 45mg in healthy subjects led to reduced resting and exercise heart rates, did not interfere with ventilation variables or tolerance to exercise, having minimal untoward effects. These results suggest the need for further studies aimed at the evaluation of pyridostigmine’s effects in cardiovascular patients, with the perspective of pharmacological modification of the autonomic nervous system possibly favorably affecting the prognosis of such conditions.

References


32. Limbruno U, Strata G, Zucchi R, et al. Altered autonomic cardiac control during cholinergic stimulation with pyridostigmine at the dose of 45mg in healthy subjects led to reduced resting and exercise heart rates, did not interfere with ventilation variables or tolerance to exercise, having minimal untoward effects. These results suggest the need for further studies aimed at the evaluation of pyridostigmine’s effects in cardiovascular patients, with the perspective of pharmacological modification of the autonomic nervous system possibly favorably affecting the prognosis of such conditions.